Retractable Technologies, Inc. (RVP)

Over the past six months, Retractable Technologies, Inc. reported its third-quarter 2025 results on November 14, 2025, with total net sales of $10.1 million and an operating loss of $3.7 million. On August 14, 2025, it released its second-quarter 2025 earnings, reporting total net sales of $10.4 million and an operating loss of $5.1 million. The first-quarter 2025 results, reported on May 15, 2025, showed total net sales of $8.3 million and an operating loss of $4.7 million. The company announced a workforce reduction of approximately 7%, expected to save an estimated $1.6 million in annual wages and benefits. Dividends were declared for Series II and Series III Class B Convertible Preferred Stock on September 30, 2025, and November 14, 2025. The stock price declined by 6.63% between January 7, 2025, and January 6, 2026, but outperformed the S&P500 Index by 7.74% over the past six months.

Explicit information regarding the demand seasonality for Retractable Technologies, Inc.'s products and services is not detailed in the provided search results. The company experienced a "massive demand surge during the COVID-19 pandemic" in 2020, highlighting that public health crises can significantly impact the demand for its safety syringes. Demand may generally be driven by ongoing healthcare needs and regulatory requirements for safety devices rather than strong seasonal patterns.

Retractable Technologies, Inc. (RVP) is a U.S.-based medical device company focused on safety-engineered injection devices and other safety medical products for the healthcare industry. The company's major product lines include injection devices, blood collection devices, and IV catheters marketed under the VanishPoint, Patient Safe, and EasyPoint brands. These products feature needle retraction systems to prevent needlestick injuries and product reuse.

Retractable Technologies, Inc. is headquartered in Little Elm, Texas, USA, and distributes its products nationally through numerous distributors with agreements across North America and select international markets. In the third quarter of fiscal year 2025, 81.27% of its revenue came from the United States, 16.71% from North and South America (excluding the U.S.), and 2.02% from other international markets.

Retractable Technologies, Inc. received an "Innovative Technology" designation from Vizient® for its EasyPoint® Blood Collection Tube Holder with Needle. The company's core mission is to protect healthcare workers and patients from sharps injuries and bloodborne infections through innovative safety solutions. There is no explicit negative information regarding its brand reputation in the provided search results for the past year.

Retractable Technologies, Inc. has 45 institutional owners and shareholders holding 2,613,205 shares, representing 7.58% of the company's stock. Major institutional owners include Vanguard Group Inc, Renaissance Technologies Llc, Eversept Partners, LP, BlackRock, Inc., Geode Capital Management, Llc, and Bridgeway Capital Management Inc. Thomas J. Shaw, the company's Chairman of the Board, President, Chief Executive Officer, and Founder, holds 16.33 million shares as of September 29, 2025.